From SARS to MERS, Thrusting Coronaviruses into the Spotlight

Coronaviruses (CoVs) have formerly been regarded as relatively harmless respiratory pathogens to humans. However, two outbreaks of severe respiratory tract infection, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), as a result of zoonotic CoVs crossing the species barrier, caused high pathogenicity and mortality rates in human populations. This brought CoVs global attention and highlighted the importance of controlling infectious pathogens at international borders. In this review, we focus on our current understanding of the epidemiology, pathogenesis, prevention, and treatment of SARS-CoV and MERS-CoV, as well as provides details on the pivotal structure and function of the spike proteins (S proteins) on the surface of each of these viruses. For building up more suitable animal models, we compare the current animal models recapitulating pathogenesis and summarize the potential role of host receptors contributing to diverse host affinity in various species. We outline the research still needed to fully elucidate the pathogenic mechanism of these viruses, to construct reproducible animal models, and ultimately develop countermeasures to conquer not only SARS-CoV and MERS-CoV, but also these emerging coronaviral diseases.

[1]  T. Kuiken,et al.  Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets , 2008, Veterinary pathology.

[2]  L. Bao,et al.  Comparative pathology of rhesus macaque and common marmoset animal models with Middle East respiratory syndrome coronavirus , 2017, PloS one.

[3]  Xi Rao,et al.  Identification of Two Critical Amino Acid Residues of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Its Variation in Zoonotic Tropism Transition via a Double Substitution Strategy , 2005, Journal of Biological Chemistry.

[4]  B. Murphy,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters , 2005, Journal of Virology.

[5]  J. Lepault,et al.  Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[7]  T. Slezak,et al.  Cynomolgus Macaque as an Animal Model for Severe Acute Respiratory Syndrome , 2006, PLoS medicine.

[8]  D. Hui,et al.  Middle East respiratory syndrome , 2015, The Lancet.

[9]  N. Zhong,et al.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.

[10]  Jiang Gu,et al.  Pathology and Pathogenesis of Severe Acute Respiratory Syndrome , 2007, The American Journal of Pathology.

[11]  Ralph S. Baric,et al.  A decade after SARS: strategies for controlling emerging coronaviruses , 2013, Nature Reviews Microbiology.

[12]  Shibo Jiang,et al.  Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein , 2006, The Journal of Immunology.

[13]  Jincun Zhao,et al.  Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected Mice , 2009, PLoS pathogens.

[14]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[15]  N. Espina,et al.  Mice Susceptible to SARS Coronavirus , 2004, Emerging infectious diseases.

[16]  Yanchen Zhou,et al.  Protease inhibitors targeting coronavirus and filovirus entry , 2015, Antiviral Research.

[17]  G. Gao,et al.  Structural Basis for Coronavirus-mediated Membrane Fusion , 2004, Journal of Biological Chemistry.

[18]  R. Baric,et al.  Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.

[19]  Malik Peiris,et al.  Aetiology: Koch's postulates fulfilled for SARS virus , 2003, Nature.

[20]  L. Lai,et al.  Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein , 2004, Biochemical and Biophysical Research Communications.

[21]  Shibo Jiang,et al.  A Conformation-Dependent Neutralizing Monoclonal Antibody Specifically Targeting Receptor-Binding Domain in Middle East Respiratory Syndrome Coronavirus Spike Protein , 2014, Journal of Virology.

[22]  Zhiwei Chen,et al.  Epithelial Cells Lining Salivary Gland Ducts Are Early Target Cells of Severe Acute Respiratory Syndrome Coronavirus Infection in the Upper Respiratory Tracts of Rhesus Macaques , 2011, Journal of Virology.

[23]  R. L. Roper,et al.  SARS vaccines: where are we? , 2009, Expert review of vaccines.

[24]  Jincun Zhao,et al.  Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models. , 2018, Journal of thoracic disease.

[25]  Jian-Piao Cai,et al.  Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset , 2015, The Journal of infectious diseases.

[26]  A. Abbas,et al.  Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein , 2017, Scientific Reports.

[27]  W. Wimley,et al.  Identification and Characterization of the Putative Fusion Peptide of the Severe Acute Respiratory Syndrome-Associated Coronavirus Spike Protein , 2005, Journal of Virology.

[28]  A. Gambotto,et al.  Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice , 2014, Vaccine.

[29]  Shibo Jiang,et al.  Current advancements and potential strategies in the development of MERS-CoV vaccines , 2014, Expert review of vaccines.

[30]  Shibo Jiang,et al.  Antigenic and Immunogenic Characterization of Recombinant Baculovirus-Expressed Severe Acute Respiratory Syndrome Coronavirus Spike Protein: Implication for Vaccine Design , 2006, Journal of Virology.

[31]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[32]  H. Kita,et al.  Effects of respiratory syncytial virus infection and major basic protein derived from eosinophils in pulmonary alveolar epithelial cells (A549) , 2011, Cell biology international.

[33]  M. McNutt,et al.  Pathogenetic mechanisms of severe acute respiratory syndrome , 2007, Virus Research.

[34]  Kwok-Hung Chan,et al.  Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. , 2013, The Journal of general virology.

[35]  K. Modjarrad MERS-CoV vaccine candidates in development: The current landscape , 2016, Vaccine.

[36]  R. Baric,et al.  Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus , 2015, Proceedings of the National Academy of Sciences.

[37]  K. Subbarao,et al.  Aged BALB/c Mice as a Model for Increased Severity of Severe Acute Respiratory Syndrome in Elderly Humans , 2005, Journal of Virology.

[38]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[39]  M. Peiris,et al.  Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro , 2006, Vaccine.

[40]  R. Wunderink,et al.  MERS, SARS and other coronaviruses as causes of pneumonia , 2017, Respirology.

[41]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[42]  R. Crystal,et al.  Resolution of Primary Severe Acute Respiratory Syndrome-Associated Coronavirus Infection Requires Stat1 , 2004, Journal of Virology.

[43]  T. Greenough,et al.  Efficient Replication of Severe Acute Respiratory Syndrome Coronavirus in Mouse Cells Is Limited by Murine Angiotensin-Converting Enzyme 2 , 2004, Journal of Virology.

[44]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[45]  M. Reiter,et al.  A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses , 2005, Vaccine.

[46]  S. El-Kafrawy,et al.  Evidence for camel-to-human transmission of MERS coronavirus. , 2014, The New England journal of medicine.

[47]  Yuan Zhang,et al.  A molecular docking model of SARS-CoV S1 protein in complex with its receptor, human ACE2 , 2005, Computational Biology and Chemistry.

[48]  J. Peiris,et al.  Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome , 2003, The Lancet.

[49]  V. Brusic,et al.  SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens , 2006, Virology.

[50]  R. Brunham,et al.  Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. , 2006, The Journal of general virology.

[51]  S. Qiu,et al.  An Exposed Domain in the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Induces Neutralizing Antibodies , 2004, Journal of Virology.

[52]  Albert D. M. E. Osterhaus,et al.  SARS virus infection of cats and ferrets , 2003, Nature.

[53]  G. Gao,et al.  The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection , 2016, Vaccine.

[54]  R. Baric,et al.  Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[55]  Jincun Zhao,et al.  Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. , 2011, The Journal of clinical investigation.

[56]  B. Prabhakar,et al.  Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse® , 2006, Virology.

[57]  Z. Memish,et al.  An Observational, Laboratory-Based Study of Outbreaks of Middle East Respiratory Syndrome Coronavirus in Jeddah and Riyadh, Kingdom of Saudi Arabia, 2014 , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  D. Cummings,et al.  Hospital outbreak of Middle East respiratory syndrome coronavirus. , 2013, The New England journal of medicine.

[59]  Yonggang Liu,et al.  Civets Are Equally Susceptible to Experimental Infection by Two Different Severe Acute Respiratory Syndrome Coronavirus Isolates , 2005, Journal of Virology.

[60]  Lisa E. Gralinski,et al.  A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.

[61]  Zhènglì Shí,et al.  Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.

[62]  H. Feldmann,et al.  Domestic Pig Unlikely Reservoir for MERS-CoV , 2017, Emerging infectious diseases.

[63]  R. Baric,et al.  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease , 2007, Virus Research.

[64]  R. Brunham,et al.  Severe acute respiratory syndrome (SARS): a year in review. , 2005, Annual review of medicine.

[65]  Jing Xie,et al.  Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.

[66]  A. Curns,et al.  Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013–2014 , 2016, Emerging infectious diseases.

[67]  R. Proulx,et al.  Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets , 2004, Journal of Virology.

[68]  I. Sola,et al.  Engineering a Replication-Competent, Propagation-Defective Middle East Respiratory Syndrome Coronavirus as a Vaccine Candidate , 2013, mBio.

[69]  Ulas Bagci,et al.  Evaluation of candidate vaccine approaches for MERS-CoV , 2015, Nature Communications.

[70]  Shibo Jiang,et al.  A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity , 2006, Biochemical and Biophysical Research Communications.

[71]  J. McLellan,et al.  Host Species Restriction of Middle East Respiratory Syndrome Coronavirus through Its Receptor, Dipeptidyl Peptidase 4 , 2014, Journal of Virology.

[72]  K. Subbarao,et al.  pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN , 2004, Journal of Virology.

[73]  K. Holmes,et al.  SARS-associated coronavirus. , 2003, The New England journal of medicine.

[74]  W. Marasco,et al.  An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus , 2005, The Journal of pathology.

[75]  F. Lai,et al.  Acute renal impairment in coronavirus-associated severe acute respiratory syndrome , 2005, Kidney International.

[76]  S. Perlman,et al.  Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.

[77]  Fang Li,et al.  Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies , 2014, Journal of Virology.

[78]  R. Baric,et al.  Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge , 2008, Journal of Virology.

[79]  Michelle M. Packard,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection of Mice Transgenic for the Human Angiotensin-Converting Enzyme 2 Virus Receptor , 2006, Journal of Virology.

[80]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[81]  B. Moss,et al.  Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[82]  Zuyuan Xu,et al.  Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection. , 2004, Journal of medical microbiology.

[83]  R. Baric,et al.  Mouse Dipeptidyl Peptidase 4 Is Not a Functional Receptor for Middle East Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.

[84]  Amit Kapoor,et al.  Middle East Respiratory Syndrome Coronavirus Infection in Dromedary Camels in Saudi Arabia , 2014, mBio.

[85]  M. Peiris,et al.  Experimental Infection and Response to Rechallenge of Alpacas with Middle East Respiratory Syndrome Coronavirus , 2016, Emerging infectious diseases.

[86]  K. Shirato,et al.  Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2 , 2013, Journal of Virology.

[87]  G. Gao,et al.  Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge , 2015, EBioMedicine.

[88]  Linqi Zhang,et al.  Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 , 2013, Cell Research.

[89]  K. Subbarao,et al.  Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine , 2005, Virology.

[90]  Susan I Gerber,et al.  2014 MERS-CoV outbreak in Jeddah--a link to health care facilities. , 2015, The New England journal of medicine.

[91]  J. Segalés,et al.  An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels , 2016, Science.

[92]  K. Überla,et al.  S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients , 2004, Journal of Virology.

[93]  Wenhui Li,et al.  A 193-Amino Acid Fragment of the SARS Coronavirus S Protein Efficiently Binds Angiotensin-converting Enzyme 2* , 2004, Journal of Biological Chemistry.

[94]  T. Greenough,et al.  Pneumonitis and Multi-Organ System Disease in Common Marmosets (Callithrix jacchus) Infected with the Severe Acute Respiratory Syndrome-Associated Coronavirus , 2005, The American Journal of Pathology.

[95]  Wenhui Li,et al.  Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[96]  T. Kuiken,et al.  Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits , 2015, Journal of Virology.

[97]  Marco Vignuzzi,et al.  Engineering attenuated virus vaccines by controlling replication fidelity , 2008, Nature Medicine.

[98]  Xiaolei Yin,et al.  Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. , 2004, The Journal of infectious diseases.

[99]  Chuan Qin,et al.  MERS coronavirus induces apoptosis in kidney and lung by upregulating Smad7 and FGF2 , 2016, Nature Microbiology.

[100]  D. Dimitrov,et al.  The SARS-CoV S glycoprotein: expression and functional characterization , 2003, Biochemical and Biophysical Research Communications.

[101]  T. Kuiken,et al.  Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets , 2004, The Lancet.

[102]  J. Peiris,et al.  Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003 , 2003, The Lancet.

[103]  Krystal L. Matthews,et al.  Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. , 2014, The Journal of general virology.

[104]  Andrew Pekosz,et al.  An immunosuppressed Syrian golden hamster model for SARS-CoV infection , 2008, Virology.

[105]  Zhiwei Chen,et al.  Rhesus angiotensin converting enzyme 2 supports entry of severe acute respiratory syndrome coronavirus in Chinese macaques , 2008, Virology.

[106]  T. Greenough,et al.  Development and Characterization of a Severe Acute Respiratory Syndrome—Associated Coronavirus—Neutralizing Human Monoclonal Antibody That Provides Effective Immunoprophylaxis in Mice , 2005, The Journal of infectious diseases.

[107]  H. Doerr,et al.  Molecular and Biological Characterization of Human Monoclonal Antibodies Binding to the Spike and Nucleocapsid Proteins of Severe Acute Respiratory Syndrome Coronavirus , 2005, Journal of Virology.

[108]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[109]  B. Berkhout,et al.  Core structure of S2 from the human coronavirus NL63 spike glycoprotein. , 2006, Biochemistry.

[110]  B. Bosch,et al.  Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[111]  Honglin Chen,et al.  An Animal Model of MERS Produced by Infection of Rhesus Macaques With MERS Coronavirus , 2013, The Journal of infectious diseases.

[112]  Lisa E. Gralinski,et al.  A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.

[113]  A. McMichael,et al.  T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.

[114]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[115]  G. Olinger,et al.  Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. , 2014, The Journal of general virology.

[116]  Lu Lu,et al.  Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor , 2014, Nature Communications.

[117]  R. Baric,et al.  A mouse model for MERS coronavirus-induced acute respiratory distress syndrome , 2016, Nature Microbiology.

[118]  Joshua C. Johnson,et al.  Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease , 2015, Virology.

[119]  R. Baric,et al.  Amino Acid Substitutions in the S2 Subunit of Mouse Hepatitis Virus Variant V51 Encode Determinants of Host Range Expansion , 2007, Journal of Virology.

[120]  R. Johnston,et al.  Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants , 2006, PLoS medicine.

[121]  D. Ho,et al.  Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.

[122]  C. Burch,et al.  Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants , 2017, Journal of Virology.

[123]  J. Epstein,et al.  Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor , 2013, Nature.

[124]  R. Baric,et al.  Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease , 2011, Journal of Virology.

[125]  M. Katze,et al.  Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques , 2013, Nature Medicine.

[126]  T. Greenough,et al.  Therapy with a Severe Acute Respiratory Syndrome–Associated Coronavirus–Neutralizing Human Monoclonal Antibody Reduces Disease Severity and Viral Burden in Golden Syrian Hamsters , 2006, The Journal of infectious diseases.

[127]  K. Subbarao,et al.  Is there an ideal animal model for SARS? , 2006, Trends in Microbiology.

[128]  M. St. Claire,et al.  Severe Acute Respiratory Syndrome Coronavirus Infection in Vaccinated Ferrets , 2007, The Journal of infectious diseases.

[129]  Jianmin Wang,et al.  Human Neutralizing Monoclonal Antibody Inhibition of Middle East Respiratory Syndrome Coronavirus Replication in the Common Marmoset , 2017, The Journal of infectious diseases.

[130]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[131]  D. Dimitrov,et al.  Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies , 2007, Proceedings of the National Academy of Sciences.

[132]  Xinxia Peng,et al.  Infection with MERS-CoV Causes Lethal Pneumonia in the Common Marmoset , 2014, PLoS pathogens.

[133]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[134]  G. Gao,et al.  Crystal Structure of Severe Acute Respiratory Syndrome Coronavirus Spike Protein Fusion Core* , 2004, Journal of Biological Chemistry.

[135]  Z. Memish,et al.  Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study , 2013, The Lancet Infectious Diseases.

[136]  Zhiwei Chen,et al.  Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques , 2015, Mucosal Immunology.

[137]  K. Subbarao,et al.  Animal Models for Sars , 2006, Advances in experimental medicine and biology.

[138]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[139]  Hongbo Hu,et al.  Screening and identification of linear B-cell epitopes and entry-blocking peptide of severe acute respiratory syndrome (SARS)-associated coronavirus using synthetic overlapping peptide library. , 2005, Journal of combinatorial chemistry.

[140]  Chengsheng Zhang,et al.  Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.

[141]  Michelle M. Packard,et al.  Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.

[142]  R. Brunham,et al.  Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines. , 2008, The Journal of general virology.

[143]  S. Yi,et al.  Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[144]  Shibo Jiang,et al.  Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus , 2015, PloS one.

[145]  B. Murphy,et al.  Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS , 2004, The Lancet.

[146]  R. Baric,et al.  Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.

[147]  K. Yuen,et al.  A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein , 2015, Cell Research.

[148]  P. T. Ten Eyck,et al.  High Prevalence of MERS-CoV Infection in Camel Workers in Saudi Arabia , 2018, mBio.

[149]  M. Cho,et al.  Specific Asparagine-Linked Glycosylation Sites Are Critical for DC-SIGN- and L-SIGN-Mediated Severe Acute Respiratory Syndrome Coronavirus Entry , 2007, Journal of Virology.

[150]  George F. Gao,et al.  Structure of the Fusion Core and Inhibition of Fusion by a Heptad Repeat Peptide Derived from the S Protein of Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[151]  H. Gao,et al.  A serological survey on neutralizing antibody titer of SARS convalescent sera , 2005, Journal of medical virology.

[152]  P. Woo,et al.  SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus , 2005, Vaccine.

[153]  Jincun Zhao,et al.  DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice , 2017, Vaccine.

[154]  H. Bielefeldt-Ohmann,et al.  Infection, Replication, and Transmission of Middle East Respiratory Syndrome Coronavirus in Alpacas , 2016, Emerging Infectious Diseases.

[155]  R. Baric,et al.  A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease , 2012, Nature Medicine.

[156]  S. Gilbert,et al.  Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology , 2017, Vaccine.

[157]  C. Durinx,et al.  Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV , 2003, Critical reviews in clinical laboratory sciences.

[158]  Jing-Pian Peng,et al.  The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization , 2006, Molecular Immunology.

[159]  K. To,et al.  Active Replication of Middle East Respiratory Syndrome Coronavirus and Aberrant Induction of Inflammatory Cytokines and Chemokines in Human Macrophages: Implications for Pathogenesis , 2013, The Journal of infectious diseases.

[160]  K. To,et al.  Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response , 2014, Virology.

[161]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[162]  A. Debnath,et al.  Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development , 2013, Journal of Virology.

[163]  J. Segalés,et al.  Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels , 2016, Journal of Virology.

[164]  David K. Meyerholz,et al.  Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice , 2017, Proceedings of the National Academy of Sciences.

[165]  Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus Infection , 2014 .

[166]  J. Jan,et al.  Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV) , 2005, Journal of biomedical science.

[167]  Lu Lu,et al.  MERS-CoV spike protein: a key target for antivirals , 2017, Expert opinion on therapeutic targets.

[168]  Yan Liu,et al.  Safety and Immunogenicity from a Phase I Trial of Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine , 2007, Antiviral therapy.

[169]  T. Pan,et al.  Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) , 2016, The Journal of Biological Chemistry.

[170]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[171]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[172]  G. Gao,et al.  Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus–Derived CD8+ T Cell Epitopes and Host MHC , 2017, The Journal of Immunology.

[173]  D. Meyerholz,et al.  Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract , 2016, The American Journal of Pathology.

[174]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[175]  Jingxin Cao,et al.  Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets , 2005, Vaccine.

[176]  Wenling Wang,et al.  Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus , 2018, Emerging Microbes & Infections.

[177]  Qingling Zhang,et al.  Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS‐CoV) in SARS patients: implications for pathogenesis and virus transmission pathways , 2004, The Journal of pathology.

[178]  B. Moss,et al.  Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein , 2005, Virology.

[179]  J. Tang,et al.  SARS: clinical presentation, transmission, pathogenesis and treatment options. , 2006, Clinical science.

[180]  Z. Memish,et al.  Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy , 2013, International Journal of Infectious Diseases.

[181]  Ralph S. Baric,et al.  MyD88 Is Required for Protection from Lethal Infection with a Mouse-Adapted SARS-CoV , 2008, PLoS pathogens.

[182]  Yufei Wang,et al.  Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants , 2016, Journal of Virology.

[183]  X. L. Liu,et al.  Isolation and Characterization of Viruses Related to the SARS Coronavirus from Animals in Southern China , 2003, Science.

[184]  Christian Drosten,et al.  The Spike Protein of the Emerging Betacoronavirus EMC Uses a Novel Coronavirus Receptor for Entry, Can Be Activated by TMPRSS2, and Is Targeted by Neutralizing Antibodies , 2013, Journal of Virology.

[185]  W. Hong,et al.  Amino Acids 1055 to 1192 in the S2 Region of Severe Acute Respiratory Syndrome Coronavirus S Protein Induce Neutralizing Antibodies: Implications for the Development of Vaccines and Antiviral Agents , 2005, Journal of Virology.

[186]  H. Feldmann,et al.  The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters , 2013, PloS one.

[187]  Wenhui Li,et al.  Conformational States of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein Ectodomain , 2006, Journal of Virology.

[188]  Chuan Qin,et al.  Middle East Respiratory Syndrome Coronavirus Efficiently Infects Human Primary T Lymphocytes and Activates the Extrinsic and Intrinsic Apoptosis Pathways , 2015, The Journal of infectious diseases.

[189]  Larissa B. Thackray,et al.  CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[190]  B. Ni,et al.  Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2. , 2007, Viral immunology.

[191]  Jaap Goudsmit,et al.  Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.

[192]  Baofeng Yang,et al.  Procyanidins and butanol extract of Cinnamomi Cortex inhibit SARS-CoV infection , 2009, Antiviral Research.

[193]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[194]  B. Murphy,et al.  SARS Vaccine Protective in Mice , 2005, Emerging infectious diseases.

[195]  H. Deng,et al.  Neutralizing Antibodies in Patients with Severe Acute Respiratory Syndrome-Associated Coronavirus Infection , 2004, The Journal of Infectious Diseases.

[196]  H. Feldmann,et al.  Pneumonia from human coronavirus in a macaque model. , 2013, The New England journal of medicine.

[197]  Lianfeng Zhang,et al.  Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. , 2007, Comparative medicine.

[198]  Jincun Zhao,et al.  Receptor Variation and Susceptibility to Middle East Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.

[199]  Baoan Yang,et al.  Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines , 2005, Virology.

[200]  T. Kirikae,et al.  Fully Human Monoclonal Antibody Directed to Proteolytic Cleavage Site in Severe Acute Respiratory Syndrome (SARS) Coronavirus S Protein Neutralizes the Virus in a Rhesus Macaque SARS Model , 2011, The Journal of infectious diseases.

[201]  Y. Guan,et al.  Tropism of and Innate Immune Responses to the Novel Human Betacoronavirus Lineage C Virus in Human Ex Vivo Respiratory Organ Cultures , 2013, Journal of Virology.

[202]  Noha H Farag,et al.  Hospital-Associated Outbreak of Middle East Respiratory Syndrome Coronavirus: A Serologic, Epidemiologic, and Clinical Description , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[203]  M. St. Claire,et al.  Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys , 2004, Virology.

[204]  Huang Xiaojun,et al.  The life cycle of SARS coronavirus in Vero E6 cells† , 2004, Journal of medical virology.

[205]  Z. Memish,et al.  Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia , 2014, International Journal of Infectious Diseases.

[206]  Y. Guan,et al.  Synthetic Peptides outside the Spike Protein Heptad Repeat Regions as Potent Inhibitors of Sars-Associated Coronavirus , 2005, Antiviral therapy.

[207]  R. Crystal,et al.  Macaque Model for Severe Acute Respiratory Syndrome , 2004, Journal of Virology.

[208]  S. Perlman,et al.  Coronaviruses: An Overview of Their Replication and Pathogenesis , 2015, Methods in molecular biology.